Ohio Medicaid does not cover Zepbound when it is prescribed for weight loss. The state’s pharmacy benefit rules categorically exclude anti-obesity medications, and that exclusion applies to Zepbound (tirzepatide) no matter how high a patient’s BMI or how serious the weight-related health conditions. There is no prior authorization pathway to request, and no clinical exception a prescriber can invoke.
Why the Exclusion Is Categorical
The rule doing the work is Ohio Administrative Code 5160-9-03, which governs Ohio Medicaid’s pharmacy benefit. Drugs prescribed for the treatment of obesity are classified as “non-covered drugs” and are not even eligible for prior authorization.1Ohio Legislative Service Commission. Rule 5160-9-03 Pharmacy Services: Covered Drugs and Associated Limitations That means the exclusion isn’t a coverage decision a doctor can appeal on the merits of a particular patient. It is a category the state has closed off entirely.
Federal law lets Ohio do this. Under the Medicaid Drug Rebate Program, states generally must cover nearly all FDA-approved outpatient drugs, but weight-loss medications sit in a specific statutory carve-out that permits exclusion.2KFF. Medicaid Coverage of and Spending on GLP-1s Ohio has used that option for years. A 2017 policy review found Ohio Medicaid “explicitly excludes coverage of drugs for the treatment of obesity,”3George Washington University STOP Obesity Alliance. Medicaid Obesity Coverage Ohio and that stance hasn’t changed for weight-loss indications since.
What Ohio Medicaid Does Cover in the GLP-1 Space
Tirzepatide isn’t shut out entirely. The same molecule is marketed as Mounjaro for Type 2 diabetes, and Mounjaro sits on the Ohio Medicaid Unified Preferred Drug List with prior authorization required.4PlexusDx. GLP-1 in Ohio A November 2025 notice from Gainwell Technologies, Ohio’s single pharmacy benefit manager, spelled out that preferred GLP-1 coverage is restricted to members with a documented diagnosis of Type 2 diabetes, and that “for all other non-FDA approved uses (such as prediabetes or weight loss), coverage will not be available.”5Ohio Medicaid SPBM. Single Pharmacy Benefit Manager Public Portal
In April 2026, Ohio Medicaid opened a narrow new door for another GLP-1 drug, Wegovy (semaglutide), under a therapeutic class called “Metabolic Modifiers: GLP-1 Agonists for Non-Obesity Indications.” Coverage applies to two conditions only:
- Cardiovascular risk reduction for adults 18 and older with a BMI of at least 27 and a history of heart attack, stroke, or symptomatic peripheral artery disease, who do not have Type 1 or Type 2 diabetes and who are already on standard cardiovascular medications.
- Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), confirmed by liver biopsy within the past 24 months or by specific diagnostic criteria indicating moderate to advanced liver fibrosis.
Both pathways require clinical prior authorization, and any subsequent authorization requires proof of at least 5% weight loss from baseline plus evidence of treatment adherence.6Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes Important boundary here: this expansion covers Wegovy, not Zepbound. Even for MACE and MASH, there is no direct Ohio Medicaid coverage pathway for tirzepatide.
The Sleep Apnea Wrinkle
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first drug approved for that condition.7U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea8Eli Lilly and Company. FDA Approves Zepbound (Tirzepatide) for Obstructive Sleep Apnea Sleep apnea isn’t a weight-loss indication, so federal Medicaid rules would generally require states to cover the drug for that use.
Ohio Medicaid hasn’t implemented that coverage yet. Reporting on Ohio’s GLP-1 landscape in mid-2026 notes that “standard coverage for indications such as Obstructive Sleep Apnea remains unavailable” despite the FDA approval.9PlexusDx. GLP-1 in Ohio The gap between what federal rules require in theory and what the state has actually done could be grounds for an appeal if a prescriber believes a patient qualifies on sleep apnea grounds.
What to Do if You Need the Drug
For a weight-loss prescription, there’s nothing to appeal. The drug is categorically excluded, and no prior authorization is available. For a non-obesity indication like sleep apnea, the picture is different, and it may be worth trying:
- Your prescriber submits a prior authorization request to Gainwell Technologies electronically or by fax. Requests are processed within 24 hours and reviewed against Unified Preferred Drug List criteria.5Ohio Medicaid SPBM. Single Pharmacy Benefit Manager Public Portal
- If it’s denied, you receive a formal notice with the reason for denial and instructions for appealing.10Disability Rights Ohio. Medicaid Prior Authorization
- The appeal process depends on whether you’re in a managed care plan or in fee-for-service Medicaid. The denial notice will spell out the timeline and steps, and Disability Rights Ohio publishes guidance for people who want help navigating it.
Out-of-Pocket Options
Eli Lilly sells Zepbound vials directly through its LillyDirect platform, starting at $299 per month for the lowest dose and $449 per month for doses of 7.5 mg and above.11Eli Lilly. Zepbound Savings Without that self-pay program, the list price runs from $499 to over $1,086 per fill.12Eli Lilly. Zepbound Pricing Information One thing to know: Medicaid enrollees are not eligible for Lilly’s savings card programs, which are limited to patients with commercial insurance or no insurance at all. Zepbound is also not part of Lilly Cares, the company’s patient assistance program.
The federal TrumpRx platform, launched in early 2026, sells Zepbound directly to consumers starting at $350 per month with no insurance or income requirements, and pricing is expected to trend down to $245 per month over two years.13CNBC. Trump Eli Lilly Novo Nordisk Deal Obesity Drug Prices For Ohio Medicaid enrollees who want the drug for weight loss and can pay monthly, that is likely the most accessible route.
Is This Likely to Change?
Two federal efforts could push Ohio toward covering Zepbound for weight loss, but neither has done so yet. The CMS BALANCE model, announced in December 2025, is a voluntary five-year program to negotiate lower manufacturer prices and expand Medicaid and Medicare access to obesity drugs; the research doesn’t indicate Ohio has opted in.2KFF. Medicaid Coverage of and Spending on GLP-1s14The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most Favored Nation Pricing to American Patients13CNBC. Trump Eli Lilly Novo Nordisk Deal Obesity Drug Prices
CMS has also proposed rule CMS-4208-P, which would require state Medicaid programs to cover anti-obesity medications. As of mid-2026, it remains a proposal and has not been finalized, and the National Association of Medicaid Directors has argued states need at least two years to prepare given projected annual costs of $30 million to $126 million depending on state size.15National Association of Medicaid Directors. Optional Not Mandatory: NAMDs Recommendations on Anti-Obesity Medication Coverage Until one of these mechanisms actually forces the issue, Ohio’s exclusion of Zepbound for weight loss stands.